A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients with Chronic Myelomonocytic Leukemia (CMML)
The purpose of this study is to find out what effects, good and/or bad, the study drug has on CMML. This research is also being done to develop biomarkers that can be used to see how well the body responds to treament with 5-azacitidine.
*Subjects should have a diagnosis of CMML as defined by WHO criteria.
*Subjects should be age 18 or older.
*Subjects should not have clinically significant heart disease.
*Subjects should not have progression to AML.
*Other active malignancies (except basal cell carcinoma of the skin and carcinoma in situ of the cervix).
18 - 99
Healthy Volunteers Needed
Duration of Participation
2 years or 24 cycles
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com
University of Utah-Huntsman Cancer Institute